New Protein Risk Predicts Mortality Risk in Heart Failure Patients
By LabMedica International staff writers Posted on 02 Jan 2024 |
Heart failure (HF) is a complex clinical condition characterized by high mortality rates. Existing methods for assessing the biological complexity of HF and determining clinical strategies are somewhat inadequate. High-throughput proteomics has the potential to enhance risk prediction; however, its practical application in managing HF patients requires robust validation and proven clinical advantages. Now, researchers have developed a new protein risk score that offers improved calibration and the potential to assist healthcare providers in more accurately determining the mortality risk in individuals with HF.
Researchers from the National Institutes of Health (NIH, Bethesda, MD, USA) have developed and validated a protein risk score to stratify mortality risk in persons with heart failure using a community-based cohort of 7,289 plasma proteins in 1,351 patients with HF using the SomaScan Assay from SomaLogic (Boulder, CO, USA). In the development cohort, the team chose 38 unique proteins for inclusion in the protein risk score. This score showed good calibration, was particularly effective at reclassifying mortality risk at the extremes of the risk spectrum, and outperformed traditional clinical models in terms of clinical utility.
The research highlights the significant potential of the clinical utility of large-scale proteomic assays in improving risk prediction in HF. The tool could guide clinicians in identifying patients who may benefit from intensified medication management or those at high risk for adverse events who might need mechanical circulatory support or transplantation. Nonetheless, the predominance of participants of European descent in the study raises questions about the score's applicability across various demographics. Therefore, additional research is essential to assess the score's effectiveness in diverse populations and to establish specific risk thresholds for various medical interventions.
Latest Molecular Diagnostics News
- New Urine Test Improves Accuracy for Early Detection of Bladder Cancer in Patients with Hematuria
- New Blood Test Enables Accurate Diagnosis of Dementia and Neurological Diseases
- Low-Cost CRISPR-Based Paper Strip Test to Improve Flu Diagnosis and Surveillance
- AI-Powered Blood Test Predicts Parkinson's Seven Years before Symptoms Appear
- Rapid Diagnostic Test for Brain Tumors to Reduce Need for Invasive Surgical Biopsy
- New Blood Test Identifies Children with Rare Heart Condition
- Novel Immune-Based Biomarker Helps Detect Ovarian Cancer Years before Diagnosis
- Advanced Liquid Biopsy Technology Detects Cancer Earlier Than Conventional Methods
- Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection
- Four-In-One Molecular Test Detects and Differentiates Among Most Prevalent Respiratory Viruses in 20 Minutes
- First-Line PSA Testing More Cost-Effective Than First-Line MRI for Prostate Cancer Screening
- Proteomics Platform Identifies Proteins in Blood to Give Cancer Warning 7 Years before Diagnosis
- AI Technology-Based Blood Test Identifies Lung Cancer Earlier
- Ultra-Sensitive Blood Test Predicts Breast Cancer Recurrence Months or Even Years before Relapse
- Prenatal Testing Offers Window for Finding Mother’s Cancer Risk
- New Molecular Test Detects More Cervical Cancer Cases